Tymara Berry

633 total citations
27 papers, 233 citations indexed

About

Tymara Berry is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Tymara Berry has authored 27 papers receiving a total of 233 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Hematology, 21 papers in Genetics and 6 papers in Molecular Biology. Recurrent topics in Tymara Berry's work include Acute Myeloid Leukemia Research (15 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (15 papers) and Chronic Myeloid Leukemia Treatments (12 papers). Tymara Berry is often cited by papers focused on Acute Myeloid Leukemia Research (15 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (15 papers) and Chronic Myeloid Leukemia Treatments (12 papers). Tymara Berry collaborates with scholars based in United States, Italy and France. Tymara Berry's co-authors include Claire Harrison, Jean‐Jacques Kiladjian, Srđan Verstovšek, Alessandro M. Vannucchi, Ruben A. Mesa, Nicolaas Schaap, Sonja Zweegman, Shelonitda Rose, Carrie Brownstein and Francesco Passamonti and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Frontiers in Oncology.

In The Last Decade

Tymara Berry

25 papers receiving 233 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tymara Berry United States	8	171	159	116	57	29	27	233
Denise Wolleschak Germany	9	86 0.5×	85 0.5×	84 0.7×	35 0.6×	19 0.7×	25	157
Pencho Georgiev Bulgaria	11	127 0.7×	230 1.4×	97 0.8×	49 0.9×	33 1.1×	30	333
Faye Feller United States	7	97 0.6×	124 0.8×	110 0.9×	24 0.4×	18 0.6×	25	187
K.-A. Kreuzer Germany	3	103 0.6×	162 1.0×	90 0.8×	27 0.5×	9 0.3×	5	210
Jeffrey Skinner United States	6	162 0.9×	188 1.2×	24 0.2×	94 1.6×	40 1.4×	16	220
Blanka Kubešová Czechia	3	245 1.4×	191 1.2×	142 1.2×	88 1.5×	12 0.4×	6	257
Evgeni Chubar Israel	7	44 0.3×	95 0.6×	69 0.6×	12 0.2×	43 1.5×	15	124
Benedetta Sordi Italy	4	140 0.8×	118 0.7×	78 0.7×	54 0.9×	7 0.2×	9	169
Sivahari Prasad Gorantla Germany	7	54 0.3×	83 0.5×	70 0.6×	29 0.5×	41 1.4×	24	162
Olivier Mansier France	7	109 0.6×	102 0.6×	80 0.7×	51 0.9×	11 0.4×	15	164

Countries citing papers authored by Tymara Berry

Since Specialization

Citations

This map shows the geographic impact of Tymara Berry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tymara Berry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tymara Berry more than expected).

Fields of papers citing papers by Tymara Berry

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tymara Berry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tymara Berry. The network helps show where Tymara Berry may publish in the future.

Co-authorship network of co-authors of Tymara Berry

This figure shows the co-authorship network connecting the top 25 collaborators of Tymara Berry. A scholar is included among the top collaborators of Tymara Berry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tymara Berry. Tymara Berry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sun, Libo, Fei Huang, Robert Kleiman, et al.. (2025). Low Proarrhythmic Risk of Imetelstat, a Novel Oligonucleotide Telomerase Inhibitor: A Translational Analysis. Clinical and Translational Science. 18(2). e70169–e70169.

Mascarenhas, John, Salman Otoukesh, Terrence Bradley, et al.. (2024). Trial Update from IMproveMF, an Ongoing, Open-Label, Dose-Escalation and -Expansion, Phase 1/1B Trial to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Novel Combination of Imetelstat with Ruxolitinib in Patients with Intermediate-1, Intermediate-2, or High-Risk Myelofibrosis (MF). Blood. 144(Supplement 1). 998–998. 1 indexed citations

Huang, Fei, Ying Wan, Libo Sun, et al.. (2024). Imetelstat, a novel, first‐in‐class telomerase inhibitor: Mechanism of action, clinical, and translational science. Clinical and Translational Science. 17(11). e70076–e70076. 12 indexed citations

Mascarenhas, John, Claire Harrison, Prithviraj Bose, et al.. (2024). Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed or Refractory to Janus Kinase Inhibitor in IMpactMF, a Randomized, Open-Label, Phase 3 Trial. Blood. 144(Supplement 1). 1808.1–1808.1. 3 indexed citations

Huang, Fei, Ying Wan, Libo Sun, et al.. (2024). Population pharmacokinetics of imetelstat, a first‐in‐class oligonucleotide telomerase inhibitor. CPT Pharmacometrics & Systems Pharmacology. 13(7). 1264–1277. 4 indexed citations

Komrokji, Rami S., Valeria Santini, Pierre Fenaux, et al.. (2023). Efficacy of Imetelstat in Achieving Red Blood Cell Transfusion Independence (RBC-TI) across Different Risk Subgroups in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis-Stimulating Agents (ESAs) in IMerge Phase 3 Study. Blood. 142(Supplement 1). 194–194. 1 indexed citations

Kuykendall, Andrew, Terrence Bradley, Rami S. Komrokji, et al.. (2023). PB2221: AN OPEN-LABEL, PHASE 1/1B STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND CLINICAL ACTIVITY OF IMETELSTAT IN COMBINATION WITH RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS: IMPROVEMF. HemaSphere. 7(S3). e906057e–e906057e. 1 indexed citations

Mascarenhas, John, Claire Harrison, Jean‐Jacques Kiladjian, et al.. (2023). PB2225: A RANDOMIZED OPEN-LABEL, PHASE 3 STUDY OF IMETELSTAT VS BEST AVAILABLE THERAPY IN INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS RELAPSED/REFRACTORY TO JAK INHIBITOR (IMPACTMF). HemaSphere. 7(S3). e99899f4–e99899f4. 1 indexed citations

Sekeres, Mikkael A., María Díez‐Campelo, Amer M. Zeidan, et al.. (2023). Improvement of Patient-Reported Outcomes Among Heavily Pretreated Patients with Lower-Risk Myelodysplastic Syndromes and High Transfusion Burden Treated with Imetelstat on the IMerge Phase 3 Trial. Blood. 142(Supplement 1). 6479–6479.

10.

Zeidan, Amer M., Uwe Platzbecker, Valeria Santini, et al.. (2023). IMerge: Results from a phase 3, randomized, double-blind, placebo-controlled study of imetelstat in patients (pts) with heavily transfusion dependent (TD) non-del(5q) lower-risk myelodysplastic syndromes (LR-MDS) relapsed/refractory (R/R) to erythropoiesis stimulating agents (ESA).. Journal of Clinical Oncology. 41(16_suppl). 7004–7004. 4 indexed citations

11.

Platzbecker, Uwe, Rami S. Komrokji, Pierre Fenaux, et al.. (2022). Imetelstat Achieved Prolonged, Continuous Transfusion Independence (TI) in Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndrome (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs) within the IMerge Phase 2 Study. Blood. 140(Supplement 1). 1106–1108. 6 indexed citations

12.

Mascarenhas, John, Claire Harrison, Jean‐Jacques Kiladjian, et al.. (2022). Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design. Future Oncology. 18(22). 2393–2402. 22 indexed citations

13.

Santini, Valeria, Pierre Fenaux, Koen Van Eygen, et al.. (2021). On-Target Activity of Imetelstat Correlates with Clinical Benefits, Including Overall Survival (OS), in Heavily Transfused Non-Del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs). Blood. 138(Supplement 1). 2598–2598. 4 indexed citations

14.

Harrison, Claire, Nicolaas Schaap, Alessandro M. Vannucchi, et al.. (2020). Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure. American Journal of Hematology. 95(6). 594–603. 104 indexed citations

15.

Mascarenhas, John, Claire Harrison, Jean‐Jacques Kiladjian, et al.. (2020). A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase (JAK) Inhibitor. Blood. 136(Supplement 1). 43–44. 7 indexed citations

16.

Harrison, Claire, Nicolaas Schaap, Alessandro M. Vannucchi, et al.. (2019). Fedratinib Induces Spleen Responses and Reduces Symptom Burden in Patients with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Low Platelet Counts, who were Either Ruxolitinib-Naïve or were Previously Treated with Ruxolitinib. Blood. 134(Supplement_1). 668–668. 13 indexed citations

17.

Harrison, Claire, Nicolaas Schaap, Alessandro M. Vannucchi, et al.. (2019). Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm (MPN)-Associated Intermediate- or High-Risk Myelofibrosis (MF) Resistant or Intolerant to Ruxolitinib: An Updated Analysis of the Phase II JAKARTA2 Study. Clinical Lymphoma Myeloma & Leukemia. 19. S356–S356. 6 indexed citations

18.

Harrison, Claire, Nicolaas Schaap, Alessandro M. Vannucchi, et al.. (2019). Fedratinib Induces Spleen Responses and Reduces Symptom Burden as First-line or Salvage Therapy in Patients with Myeloproliferative Neoplasm-Associated Intermediate- or High-Risk Myelofibrosis (MF) and Low Platelet Counts. Clinical Lymphoma Myeloma & Leukemia. 19. S355–S355. 6 indexed citations

19.

Gajra, Ajeet, Nagla Abdel Karim, Deborah Mulford, et al.. (2018). nab-Paclitaxel–Based Therapy in Underserved Patient Populations: The ABOUND.PS2 Study in Patients With NSCLC and a Performance Status of 2. Frontiers in Oncology. 8. 253–253. 10 indexed citations

20.

Langer, Corey J., Edward S. Kim, Eric Anderson, et al.. (2018). nab-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.70+ Study in Elderly Patients With Advanced NSCLC. Frontiers in Oncology. 8. 262–262. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact